FDA has approved Fast Track designation for bemcentinib for treatment of elderly patients with acute myeloid leukaemia (AML) whose disease has relapsed.
In light of new FDA labeling recommendations for saline and silicone gel-filled breast implants, FDA officials Amy Abernethy and Jeffrey E. Shuren issued a statement outlining the agency's recommendations for manufacturers.
For the first time, FDA has authorized the marketing of products through the modified risk tobacco product pathway. The authorizations are for eight Swedish Match USA, Inc. snus smokeless tobacco products sold under the “General” brand name.
The phase III IMbrave150 study evaluating Tecentriq in combination with Avastin in people with unresectable hepatocellular carcinoma met its co-primary endpoints of overall survival and progression-free survival, compared with standard-of-care sorafenib.
Wide Field Optical Coherence Tomography has the potential to significantly reduce the need for additional surgery after breast tumor resection, according to a study published in The Breast Journal.
Researchers at The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute report a discovery that helps scientists understand why some tumors lack immune cell infiltration and are therefore unresponsive to newer PD-1 targeted therapies.
Researchers have found an antibody, imatinib, that eliminates chronic myeloid leukemia stem cells in mice and isolated human cancer cells and could keep one form of the disease from persisting after treatment.
A phase 3 clinical trial, CheckMate-9LA, evaluating Bristol-Myers Squibb's Opdivo (nivolumab) + low-dose Yervoy (ipilimumab), together with two cycles of chemo, for the first-line treatment of advanced non-small cell lung cancer met the primary endpoint of overall survival compared to chemo alone for up to four cycles followed by optional maintenance therapy.
Barry Paul Sleckman was named director of the O'Neal Comprehensive Cancer Center at the University of Alabama at Birmingham.
Michael Birrer was named vice chancellor and director of the Winthrop P. Rockefeller Cancer Institute at the University of Arkansas for Medical Sciences. Birrer specializes in gynecologic cancers and will join the university by the end of the year.
